Olaparib (AZD2281)

For research use only.

Catalog No.S1060 Synonyms: Ku-0059436

517 publications

Olaparib (AZD2281) Chemical Structure

CAS No. 763113-22-0

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 57 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Olaparib (AZD2281) has been cited by 517 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)		 PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NX\vVmVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TW[lQh\A>? NH7sPGZKSzVyPUWuO|A2KCEQvF2g NYfjdHF7OTh3NUm2NVM>
KP6.3 NWjETJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjmU5E1KGR? M2XpTWlEPTB;MUCuOFI5KM7:TTC= NXu4WJJ1OTh3NUm2NVM>
KP7.7 M1[zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjPU4E1KGR? MUTJR|UxRTV5IH7NJC=> NIrhW|EyQDV3OU[xNy=>
KB2P3.4 NWLsR4l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[ydFQh\A>? MULJR|UxRTF{NDDNJC=> NY\GcXpVOTh3NUm2NVM>
KB2P1.21 MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDVbIFkPCCm NYHrO5J4UUN3ME24PVA4KG6PIB?= Mlz2NVg2PTl4MUO=
U373-MG MYfDfZRwfG:6aXOgRZN{[Xl? MU[xJO69VSB? MkXmNlQhcA>? MoTxTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NWf0SYN{OTh7NUS3NVI>
T98G NF3MblBEgXSxdH;4bYMhSXO|YYm= MkjkNUDPxE1i NWfzepBqOjRiaB?= NGD5eZZKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NIrjeFUyQDl3NEexNi=>
U87-MG M4DvbmN6fG:2b4jpZ{BCe3OjeR?= M4X0PFEh|ryPIB?= NEDZZ3UzPCCq MnT5TY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? MXixPFk2PDdzMh?=
UVW MWXDfZRwfG:6aXOgRZN{[Xl? MoO1OVAxKG6P MojjNlQhcA>? MnewTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? Mmq4NVg6PTR5MUK=
HeLa Ml71SpVv[3Srb36gRZN{[Xl? Mn;lOVAxKG6P NF\hV4w1KGh? M1rET2NifXOnczDhJI1w\GW|dDDk[YxigSCrbjDy[YpwcW6rbnegc4YhemGmaXH0bY9vNWmwZIXj[YQhTE6DIHLy[YFsew>? NFj5cmQyQDl3NEexNi=>
HeLa MoTISpVv[3Srb36gRZN{[Xl? M{WycFEh|ryPIB?= NVfnNFJmOjRiaB?= NYrtVJJuTW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S= NX7Od3l1OTh7NUS3NVI>
T98G NXvUTFhuTnWwY4Tpc44hSXO|YYm= MmfONUDPxE1i NYT5[VQxOjRiaB?= MWLFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? NVvqVppLOTh7NUS3NVI>
L3 Mmq2R5l1d3SxeHnjJGF{e2G7 NVTBW4FrPSEQvF2g MnjtPVYhcA>? MnfoSG1UVw>? MlrnV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs NWHtU4QzOjBzMkS0OVk>
Granta-519 MnzkR5l1d3SxeHnjJGF{e2G7 Mo\JOUDPxE1i NF;NPGE6PiCq M4jpeWROW09? NIO1bmZUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NWDBWoprOjBzMkS0OVk>
BT NXTXN5FbS3m2b4TvfIlkKEG|c3H5 NUPi[o84PSEQvF2g NX\IdVNuQTZiaB?= MoS1SG1UVw>? MVnTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MUCyNFEzPDR3OR?=
UPN2 NVu1eFdZS3m2b4TvfIlkKEG|c3H5 NUTwbYEyPSEQvF2g MUC5OkBp MWfEUXNQ NWe1PZhuW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= NHPVW4IzODF{NES1PS=>
HBL-2 NFe1W3BEgXSxdH;4bYMhSXO|YYm= M3jGUVUh|ryPIB?= M1HmV|k3KGh? NUjKO484TE2VTx?= M{XIUXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? M37YV|IxOTJ2NEW5
JVM-2 M1Xh[WN6fG:2b4jpZ{BCe3OjeR?= NIDhTIM2KM7:TTC= M1z1S|k3KGh? M3Ple2ROW09? NWHNXIJCW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MkDwNlAyOjR2NUm=
Z138 MYDDfZRwfG:6aXOgRZN{[Xl? MoD1OUDPxE1i M1LYOVk3KGh? NGH0V4pFVVOR NH7VZWJUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NVTEeotbOjBzMkS0OVk>
RWPE MX\JcpZie2m4ZTDBd5NigQ>? MUCyOUDPxE1? NGr3bms1QCCq MnfBSG1UVw>? NH\HO4lUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v NYPtdpBPOjF3N{W4OlU>
VCaP M37wdWlvfmG|aY\lJGF{e2G7 NUfGPZM1OjVizszN M4LTd|Q5KGh? MnTvSG1UVw>? NYPlPGNTW2mpbnnmbYNidnSueTDy[YR2[2W|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>? MXiyNVU4PTh4NR?=
Mouse H2AX−/− ES Cells MmDNR5l1d3SxeHnjJGF{e2G7 NEHUZ20zNjVizszN M3\rOFIxKGh? NVLCNmNpW2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MUCyN|M2PTR6OR?=
Mouse ATM−/− ES Cells M{\aT2N6fG:2b4jpZ{BCe3OjeR?= Mn36Nk42KM7:TR?= Mm\rNlAhcA>? Ml62V4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs MVmyN|M2PTR6OR?=
H1650 NGHLc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XQ[lIxKM7:TR?= NHKwe2gyPDRiaB?= Mnz6TWM2OD1zNT60O{DPxE1? NGTMfZgzOzJ|OUiwPS=>
H1650PTEN+ M{mwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXINlAh|ryP NHHTO3UyPDRiaB?= M1rTdWlEPTB;NUCuPFMh|ryP MVqyN|I{QThyOR?=
PC-9 M4nIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXWeXRUOjBizszN NXXOcHF6OTR2IHi= NHXyfm5KSzVyPUWuPFgh|ryP NIezRpczOzJ|OUiwPS=>
PC-9PTEN− NHrUe5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX4[4RpOjBizszN MYWxOFQhcA>? MV7JR|UxRTZwNUKg{txO MUeyN|I{QThyOR?=
MDA-MB-231 NETJXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG1JIRigQ>? M1nuXmlEPTB;Nj65JO69VQ>? MU[yN|c3ODR7Nh?=
MDA-MB-468 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\QO5VSPSCmYYm= MWLJR|UxRTVwMDFOwG0> MVWyN|c3ODR7Nh?=
BT20 NFywdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP0OUBl[Xl? MVvJR|UxRTdwNzFOwG0> MnnxNlM4PjB2OU[=
HCC1143 NUXDcFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqxOUBl[Xl? MVzJR|UxRTFzLkGg{txO M2rpO|I{PzZyNEm2
HCC1937 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrnO5Q2KGSjeR?= NV;TbXd7UUN3ME2xNk43KM7:TR?= MojrNlM4PjB2OU[=
Hs578t NWXsdm5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zvelUh\GG7 MmfxTWM2OD13Lk[g{txO NUX1dJRyOjN5NkC0PVY>
Hs578t(si) MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPUUIEzPSCmYYm= NXTrZmQxUUN3ME23MlUh|ryP NH3VSWwzOzd4MES5Oi=>
BT474 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTTS21yPSCmYYm= NWjLWGZOUUN3ME2xPU45KM7:TR?= NX\Rem93OjN5NkC0PVY>
JIMT1 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTZOUBl[Xl? M1z4UGlEPTB;Nz63JO69VQ>? MoDENlM4PjB2OU[=
SKBR3 M2KySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO5OUBl[Xl? NWfVc3VRUUN3ME2xNU4yKM7:TR?= NGC3XmYzOzd4MES5Oi=>
SUM159 M4POS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7mfJg6PSCmYYm= NUjOU4pOUUN3ME20MlIh|ryP MmrONlM4PjB2OU[=
CAMA1 NIfmN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvDdoQ4PSCmYYm= MoLBTWM2OD1zNT64JO69VQ>? NGnFO5gzOzd4MES5Oi=>
MCF7 NYLGcnNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ob4c2KGSjeR?= M4\0WWlEPTB;NT64JO69VQ>? MmfFNlM4PjB2OU[=
T47D MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjBOUBl[Xl? NG\ZdHZKSzVyPUmuOkDPxE1? MVWyN|c3ODR7Nh?=
HCT116 NVv1XZVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3UN3IyODBizszN NWK3cIV6PDhiaB?= NXntd2xNTE2VTx?= M2rNcWlEPTB;Mj61JO69VSB? MWiyOFU4Pzl2MR?=
SW1116 NX7XbW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;iT49nOTByIN88US=> MmHyOFghcA>? M3fRb2ROW09? M2rBVGlEPTB;MUCwJO69VQ>? MlfvNlQ2Pzd7NEG=
HT29 NFzaXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\wUlN2OTByIN88US=> M4ftcFQ5KGh? MVrEUXNQ MlLpTWM2OD1zND63JO69VQ>? Mli1NlQ2Pzd7NEG=
LoVo M3HsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPxUHlYOTByIN88US=> NGTnT4o1QCCq NYW4PXJFTE2VTx?= NYnYfpZOUUN3ME2xN{41KM7:TR?= NEfhbHkzPDV5N{m0NS=>
HCT-15 NXT5SHM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDyRoUyODBizszN NFztRXY1QCCq MV7EUXNQ M4nPdmlEPTB;MUCg{txO NW[zW5d{OjR3N{e5OFE>
SW48 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n2V|ExOCEQvF2= MWe0PEBp M17wU2ROW09? NYP1dZByUUN3ME25MlUh|ryP NFWxZYQzPDV5N{m0NS=>
C-1 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojNNVAxKM7:TR?= MVe0PEBp Mmq3SG1UVw>? MXnJR|UxRTdwNjFOwG0> MYWyOFU4Pzl2MR?=
RKO Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq1V4pPOTByIN88US=> NUDTe5NzPDhiaB?= NHHZc3dFVVOR M1fyT2lEPTB;NT65JO69VQ>? NXf1[oV1OjR3N{e5OFE>
HCT116 M1\lemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGxNFAh|ryP Mn\iOFghcA>? MUPEUXNQ NYi3bnJ6WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MUWyOFU4Pzl2MR?=
SW1116 NHLFTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T0PFExOCEQvF2= NV[4O5JPPDhiaB?= NGWwR3RFVVOR Mmf4VI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NHK1WXczPDV5N{m0NS=>
HT29 NXfwdZFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TxZVExOCEQvF2= MnnKOFghcA>? MVLEUXNQ MXjQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MnLnNlQ2Pzd7NEG=
LoVo Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHJNVAxKM7:TR?= NEK2eo81QCCq Mlf6SG1UVw>? M{myUnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MljQNlQ2Pzd7NEG=
SW48 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSyfFA5OTByIN88US=> NIP1eVc1QCCq M17yfGROW09? NXr3cnBmWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MlTmNlQ2Pzd7NEG=
C-1 M1XjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\r[|MyODBizszN MVq0PEBp MYjEUXNQ NIfFN4hRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MlnrNlQ2Pzd7NEG=
RKO MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonvNVAxKM7:TR?= M1\FelQ5KGh? NXPPeHVuTE2VTx?= MVzQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MX6yOFU4Pzl2MR?=
HCT116 MoHUSpVv[3Srb36gRZN{[Xl? NHzGc2YyOCCwTR?= NUHxSVRbOTJiaB?= NF3xOHBFVVOR M1HFRmlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= Mkf4NlQ2Pzd7NEG=
HT29 M2jB[mZ2dmO2aX;uJGF{e2G7 NXnN[mp2OTBibl2= MkPNNVIhcA>? NX[wVYxrTE2VTx?= NITmb|hKdmO{ZXHz[ZMhTE6DIHTveYJt\S2|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i= M17JdVI1PTd5OUSx
TE-6 NUC5eWl7TnWwY4Tpc44hSXO|YYm= MYq1JO69VSB? M2DXPFEzKGh? NHnoV5lFVVOR NWTMb2NNUW6mdXPld{BIOi:PIHHydoV{fA>? M4j2PFI1OjF7MU[0
TE-6 NIDJeWdHfW6ldHnvckBCe3OjeR?= M2PiNVUh|ryPIB?= NVPBUnRpOjRiaB?= MWPEUXNQ NU\Lc4lEUW6lcnXhd4V{KGmwIHTveYJt\SC|dILhcoQh[nKnYXvzJEhFW0K|KR?= NYG3fYR5OjR{MUmxOlQ>
Hep3B NILUPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrqVGg1OCEQvF2g M2TnWlczKGh? MUHEUXNQ M2Da[nN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS NYnhW2l{OjVyN{K3OVI>
Huh7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXVNoJtPDBizszNJC=> MnrTO|IhcA>? NF\4ZVZFVVOR NX\qe2VZW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? MX6yOVA4Ojd3Mh?=
Hep3B MX3GeY5kfGmxbjDBd5NigQ>? M17aNFQxKM7:TTC= MnXsNlQhcA>? M2[wXWROW09? NYLES2Z4UW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR NYXyO|NHOjVyN{K3OVI>
Huh7 MVfGeY5kfGmxbjDBd5NigQ>? Ml\BOFAh|ryPIB?= M33VcVI1KGh? MoHzSG1UVw>? MV7JcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? NGHDVJczPTB5Mke1Ni=>
Hep3B NYT0WJJOTnWwY4Tpc44hSXO|YYm= NXXRd2V7PDBizszNJC=> NWG4blZ{OjRiaB?= MkLVSG1UVw>? M2fYOmlv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= M{\4S|I2ODd{N{Wy
Huh7 MYfGeY5kfGmxbjDBd5NigQ>? NGXHXW01OCEQvF2g MorYNlQhcA>? MoG3SG1UVw>? NWDxZo1HUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR NYDoSpJXOjVyN{K3OVI>
SGC-7901 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmzNOKh|ryP MmK4OFghcA>? MWPEUXNQ Mm\TRoxw[2tib4jhcIlxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo M1PoOVI2PzZ5MEe2
COLO-800 Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNESxOlQh|ryP NVXKSY1IW0GQR1XS
EoL-1- NUHQWnhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXZSWNqUUN3ME2wMlU3PDR4IN88US=> MV;TRW5ITVJ?
NCI-H209 NE\kT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfJWY14UUN3ME2wMlkyPTV4IN88US=> NVjtSZVVW0GQR1XS
ES1 NGm1RY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\DdmpKSzVyPUGuNVE1ODhizszN M1LZPXNCVkeHUh?=
NKM-1 NIW3TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X5bWlEPTB;MT6yOVM1PyEQvF2= NYLZV4sxW0GQR1XS
NTERA-S-cl-D1 NUTsOoNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDxNIROUUN3ME2xMlM{OzRzIN88US=> MYnTRW5ITVJ?
MHH-ES-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTuTWM2OD1zLk[yNFY4KM7:TR?= M{D4eXNCVkeHUh?=
ES8 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnze2VyUUN3ME2xMlczPDF2IN88US=> M17SN3NCVkeHUh?=
NCI-H720 NXvoOlhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfOTWM2OD1{LkKwOlk6KM7:TR?= NHXQelRUSU6JRWK=
EW-3 Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;kSWlEPTB;Mj6yO|U{PCEQvF2= NIS1V4xUSU6JRWK=
D-566MG NUDWXlFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwNES1Olgh|ryP NV;DeIhrW0GQR1XS
697 NYDvWJFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwOESxO|Mh|ryP MonCV2FPT0WU
ES5 MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHQdXRCUUN3ME2yMlg5OTh7IN88US=> MofSV2FPT0WU
COLO-684 M4PHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TPPWlEPTB;Mz61NVY6PiEQvF2= M2XhNnNCVkeHUh?=
ML-2 NX3XVGZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TNbWlEPTB;Mz62NFA2QCEQvF2= MlWxV2FPT0WU
MC-IXC NVGzVJl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTpR3h6UUN3ME2zMlY{Ozl|IN88US=> MUHTRW5ITVJ?
DB MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTNwNkW0OFgh|ryP MlL3V2FPT0WU
HCC2218 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzVbmVlUUN3ME2zMlc{OTB|IN88US=> M{Lw[nNCVkeHUh?=
NCI-H510A NWnkUIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYCyN|V6UUN3ME2zMlgzPzJ2IN88US=> M1qyNXNCVkeHUh?=
NCI-H526 NHfPeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjGUlFKSzVyPUOuPFY6PThizszN M3\ybnNCVkeHUh?=
MV-4-11 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRwMUOzN|Qh|ryP M{PrR3NCVkeHUh?=
PA-1 M1zkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXFNYxiUUN3ME20MlI2OjlizszN M1PDUnNCVkeHUh?=
EW-22 M1nVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nicmlEPTB;ND6zOVg3KM7:TR?= MXfTRW5ITVJ?
KASUMI-1 M3TLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXufItKSzVyPUSuOFAyODlizszN MmPqV2FPT0WU
LU-139 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGwOnF[UUN3ME20Mlc2QDJ7IN88US=> M2q0d3NCVkeHUh?=
SBC-1 NXe5PIx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG3TWM2OD12LkiwPVA5KM7:TR?= M2LnW3NCVkeHUh?=
H4 NHG5[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRwOEm0OFMh|ryP MlGyV2FPT0WU
EW-11 M4P3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTVwMEiwO|Ih|ryP MXzTRW5ITVJ?
NBsusSR MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[2TWM2OD13LkGyNFU2KM7:TR?= NX[0VIVoW0GQR1XS
RPMI-8226 MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7zSoFKSzVyPUWuNVUzPDRizszN M{fGc3NCVkeHUh?=
DEL NFPjXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD2TWM2OD13LkKwNFA3KM7:TR?= Mn\VV2FPT0WU
ES4 NIjn[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7VcoNoUUN3ME21MlUyOzh7IN88US=> NX72VnJ{W0GQR1XS
GCT MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnriTWM2OD13LkW2PFU3KM7:TR?= NIPsXmtUSU6JRWK=
NCI-H1048 NIHMV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPzbGFKSzVyPUWuPVczPzNizszN NELCNZVUSU6JRWK=
NCI-SNU-1 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\TRWlEPTB;Nj6wNlIh|ryP MnPuV2FPT0WU
ES7 NGHvV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4flN2lEPTB;Nj6wN|U4PyEQvF2= NWLoXY5ZW0GQR1XS
SW982 NX\tOGt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGyTGFKSzVyPU[uNFkyOzdizszN NVP6TWJxW0GQR1XS
L-363 NG\lfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fvfmlEPTB;Nj6zN|k4PCEQvF2= M{\jenNCVkeHUh?=
HT-1080 M1fTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTzSHRpUUN3ME22MlQ6Pjh|IN88US=> NVTBdlNyW0GQR1XS
HAL-01 M{LIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPwR4hKSzVyPU[uOVExQSEQvF2= MkT5V2FPT0WU
NB14 NUPTZlNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\1PWlEPTB;Nj62OFA{QSEQvF2= MU\TRW5ITVJ?
EW-13 M3WyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7Z[YpKSzVyPU[uO|c1OjRizszN MVfTRW5ITVJ?
NY M3XVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELFVYRKSzVyPU[uPVQ3ODVizszN M4LrRXNCVkeHUh?=
NCI-SNU-5 NVHkVmhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK2TWM2OD15LkGwOFM{KM7:TR?= NYT1XJY2W0GQR1XS
MS-1 M1qxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS3PId5UUN3ME23MlE4PDl2IN88US=> NVvIZ|ZPW0GQR1XS
EW-16 NWHCW29mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTdwM{G4OlEh|ryP M1[2O3NCVkeHUh?=
LU-65 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXmR5BKSzVyPUeuOFg1OTdizszN NHj3eHRUSU6JRWK=
HGC-27 MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfaO2FiUUN3ME23MlczOTd|IN88US=> NVS2NI44W0GQR1XS
CTB-1 NVK0U4NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnONGFKSzVyPUeuO|YyPzVizszN NF70S5NUSU6JRWK=
5637 M1r2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\BRmlEPTB;Nz65Nlg3KM7:TR?= MUHTRW5ITVJ?
U251 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHKTWM2OD15Lkm0NFE3KM7:TR?= MV7TRW5ITVJ?
HOS M4fOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrWTWM2OD16LkKzNFA4KM7:TR?= M33z[3NCVkeHUh?=
DOHH-2 MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e3b2lEPTB;OD6yN|U5KM7:TR?= M2X5e3NCVkeHUh?=
EW-1 M{LpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPneXdKSzVyPUiuN|AxQDhizszN M1nmbnNCVkeHUh?=
BV-173 NV;LV|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LaXGlEPTB;OD61OVU1KM7:TR?= NHTDR|ZUSU6JRWK=
8-MG-BA MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\tTGlEPTB;OD62PFk5QCEQvF2= MWPTRW5ITVJ?
NB69 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHpTWM2OD16LkewPVIyKM7:TR?= NYf3WpdNW0GQR1XS
NCI-H69 NF;0d3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7uVY5XUUN3ME25MlkxQTZzIN88US=> M{O3WnNCVkeHUh?=
RS4-11 M1HwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjodFZYUUN3ME2xNU4zOjB6IN88US=> NHjZcW9USU6JRWK=
ONS-76 NIG3TVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHDSHpYUUN3ME2xNU4zQTR5IN88US=> MXHTRW5ITVJ?
SF539 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7vcVI4UUN3ME2xNU41QDh7IN88US=> MkjqV2FPT0WU
HuO-3N1 M3\HZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\6TWM2OD1zMT61O|k3KM7:TR?= MYfTRW5ITVJ?
NCI-H1651 M2PnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO1TWM2OD1zMj6zNVE2KM7:TR?= NF;JfWVUSU6JRWK=
KARPAS-45 M2fETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF{LkO3OkDPxE1? NVrGPJNwW0GQR1XS
SK-NEP-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXJb2xKSzVyPUGyMlQ3ODlizszN MV7TRW5ITVJ?
LAMA-84 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe5d5JKSzVyPUGzMlExQTVizszN NYjUWoZrW0GQR1XS
NCI-H1155 NETZ[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojXTWM2OD1zMz6yPFU3KM7:TR?= NX65R5lYW0GQR1XS
CTV-1 NFPRNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj3T5RKSzVyPUGzMlQ1PSEQvF2= MWfTRW5ITVJ?
QIMR-WIL NXvLfGUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXraVmRjUUN3ME2xN{44QDF2IN88US=> M1HUfXNCVkeHUh?=
H9 M4PSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX22bFdxUUN3ME2xN{45PDd3IN88US=> NV31OIZNW0GQR1XS
SK-MEL-1 NGXWbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF|LkmzOFch|ryP MlLmV2FPT0WU
HD-MY-Z MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T0fmlEPTB;MUSuNFY{PyEQvF2= NFH3UHRUSU6JRWK=
TI-73 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jv[WlEPTB;MUSuNlM2PiEQvF2= NXfldXlyW0GQR1XS
JVM-3 NGDKdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPMTWM2OD1zNT61O|E3KM7:TR?= Mnq2V2FPT0WU
D-247MG M1jXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDYbmMxUUN3ME2xOU42QTNizszN NFvvOotUSU6JRWK=
VA-ES-BJ MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF3Lk[wPVch|ryP M4ryeXNCVkeHUh?=
NOS-1 NF;vUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHyNnduUUN3ME2xOU43PTJ{IN88US=> MorUV2FPT0WU
MOLT-4 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF4Lke1NkDPxE1? MmP4V2FPT0WU
Mo-T NIXHTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTG[WpKSzVyPUG3MlA5PDlizszN MWLTRW5ITVJ?
NCI-H1770 NUTwTYJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDqfXE1UUN3ME2xO{4yPTR|IN88US=> MXHTRW5ITVJ?
COLO-320-HSR M3HFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\xOmlEPTB;MUeuNVgzPyEQvF2= M335[XNCVkeHUh?=
TE-12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHCNFVQUUN3ME2xO{44ODV2IN88US=> NGS5NGxUSU6JRWK=
NCI-H82 Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvrU3RKSzVyPUG3Mlg4OjhizszN NWP3PHBnW0GQR1XS
NEC8 NFHsUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTRU2ZKSzVyPUG4MlE{OTZizszN NXv0XVE{W0GQR1XS
HSC-3 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[zZVdKSzVyPUG4Mlc1OTRizszN NHzyNWRUSU6JRWK=
NCI-H1092 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzITWM2OD1zOD63OVk2KM7:TR?= M1fmRnNCVkeHUh?=
NCI-H292 M33iNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF7LkC0PFkh|ryP NFPwbIVUSU6JRWK=
L-428 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj3So9KSzVyPUG5MlU2QSEQvF2= MYXTRW5ITVJ?
LU-134-A MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPXbW1TUUN3ME2xPU42PzJizszN MWjTRW5ITVJ?
GI-ME-N NYK5bGdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF7LkW3OFch|ryP NEfpT29USU6JRWK=
ALL-PO NXL6e5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPD[ldrUUN3ME2xPU42QTd{IN88US=> NUHIOW5uW0GQR1XS
D-283MED NWnLbFBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFSweXdKSzVyPUG5MlkyPSEQvF2= NX2xcYtDW0GQR1XS
D-423MG M4DLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[zTWM2OD1zOT65PVY4KM7:TR?= MoTKV2FPT0WU
CAKI-1 NEPEUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jOUWlEPTB;MkCuNlIyQSEQvF2= NVvkTnlLW0GQR1XS
ETK-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnQXYhpUUN3ME2yNE4zPjF3IN88US=> NFr6OmhUSU6JRWK=
G-402 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzwTWM2OD1{MD61N|M1KM7:TR?= Mn;GV2FPT0WU
HL-60 NXvqNW9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f0dGlEPTB;MkGuNVYyOyEQvF2= NFrZe29USU6JRWK=
A2058 NYfaU5ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETGT3JKSzVyPUKxMlQ1PzdizszN Mn3iV2FPT0WU
CHP-212 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJzLkmwOVEh|ryP M4TrbXNCVkeHUh?=
KY821 NUS2W5RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnQOoRKSzVyPUKxMlk4PSEQvF2= Mk[2V2FPT0WU
TYK-nu NV7uXXI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ{LkC2OVEh|ryP NFfmXWpUSU6JRWK=
JVM-2 NH3yW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ{LkK5PFMh|ryP MVjTRW5ITVJ?
KU812 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHK[HFKSzVyPUKyMlc{OTJizszN M4m3N3NCVkeHUh?=
MKN28 NFHXWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorpTWM2OD1{Mj65NFE2KM7:TR?= NGLrWlNUSU6JRWK=
ECC10 NGXPdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PRZmlEPTB;MkOuO|QyKM7:TR?= MV7TRW5ITVJ?
BHT-101 M3q1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M160T2lEPTB;MkSuNFAxQCEQvF2= MonVV2FPT0WU
DU-4475 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjjcWdKSzVyPUK0MlM{OzdizszN MlLBV2FPT0WU
769-P NFjuSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ2Lki0OlYh|ryP MV;TRW5ITVJ?
HEC-1 MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ3LkS0OUDPxE1? NXHQZ3BpW0GQR1XS
MOLT-13 M1\Odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDUeZdFUUN3ME2yOU42OzNzIN88US=> NHLjdHVUSU6JRWK=
8505C NHTtenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjBd21TUUN3ME2yOk41QTd5IN88US=> MlXkV2FPT0WU
GB-1 NVzrWVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ4LkexO|Yh|ryP NF31cFNUSU6JRWK=
SF126 NETQ[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ4Lke2OFgh|ryP MVfTRW5ITVJ?
A4-Fuk M3PGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T3eWlEPTB;MkeuNVI4OSEQvF2= M{nnTXNCVkeHUh?=
OVCAR-8 M4DBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDZTWM2OD1{Nz6xOVM6KM7:TR?= MXnTRW5ITVJ?
NCI-H1304 NWTu[5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ5LkW0JO69VQ>? Mnz4V2FPT0WU
GR-ST MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfiTWM2OD1{OD6wOFch|ryP NHrnd2ZUSU6JRWK=
G-401 M4XxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ6LkWwPVYh|ryP NED0VYpUSU6JRWK=
LXF-289 NEL5ZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HkdWlEPTB;MkiuOVY2OSEQvF2= MWjTRW5ITVJ?
DBTRG-05MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ6LkmyNFQh|ryP MlH6V2FPT0WU
YKG-1 NGHCU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i3emlEPTB;MkmuPFY5KM7:TR?= MlfTV2FPT0WU
GAMG NIDocIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJ7Lkm5N{DPxE1? MXfTRW5ITVJ?
HCT-116 NUKweGU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XMOGlEPTB;M{CuNFU1QCEQvF2= NFzndGtUSU6JRWK=
S-117 NG\SfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHOTWM2OD1|MT6yNlU4KM7:TR?= NXLq[FFpW0GQR1XS
NCI-H1693 M1y2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN|Lk[1OFIh|ryP Mnf4V2FPT0WU
A427 NVfkWGNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPwUFQ3UUN3ME2zN{46QTd4IN88US=> NWn3cnZkW0GQR1XS
HT-29 NEX0TllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PKVWlEPTB;M{SuOlA{OiEQvF2= NWLWTopMW0GQR1XS
P12-ICHIKAWA Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPGTWM2OD1|ND63OFkyKM7:TR?= M4\yPHNCVkeHUh?=
CAL-51 NWrZSVVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPFTWM2OD1|NT6wO|A6KM7:TR?= M1iyXXNCVkeHUh?=
Ramos-2G6-4C10 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjOeIFKSzVyPUO1MlI1OjVizszN M2XvOnNCVkeHUh?=
SCH M{TrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrMT4RKSzVyPUO2MlQyPzRizszN MnzDV2FPT0WU
SK-MEL-24 NWjxWoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTaSpdKSzVyPUO2MlkxPDRizszN MX;TRW5ITVJ?
SW1573 M3j5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;aTWM2OD1|OD63NlE3KM7:TR?= MmjLV2FPT0WU
BALL-1 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN7LkKxNlkh|ryP MWPTRW5ITVJ?
BE-13 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN7LkOyPUDPxE1? M1zDSnNCVkeHUh?=
GI-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTN7Lki2OFch|ryP NGrQVXlUSU6JRWK=
GOTO NWiwcG4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nx[mlEPTB;M{muPVE{QSEQvF2= M1O1cnNCVkeHUh?=
A673 NX24WmsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTRzLkCzOFMh|ryP NFfCWHZUSU6JRWK=
KG-1 NV;KZZZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR|LkO5OEDPxE1? NYnJRoVUW0GQR1XS
GP5d M4fkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKxemV6UUN3ME20OE4xPjZ4IN88US=> MnK2V2FPT0WU
MFM-223 NX;DVFROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoSxTWM2OD12ND6xNlI5KM7:TR?= MkHNV2FPT0WU
OAW-42 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\QWmlEPTB;NESuNlY1OyEQvF2= NWPYXo9RW0GQR1XS
C8166 NGDOWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS4TWM2OD12NT6wPFIzKM7:TR?= NFjSOGpUSU6JRWK=
LU-99A MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjMSJlKSzVyPUS2MlE{OjJizszN M1vvOXNCVkeHUh?=
NCI-H23 M2\WUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPITWM2OD12Nj6xO|g2KM7:TR?= NHXkc2FUSU6JRWK=
HO-1-N-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTR5LkC5PVgh|ryP MVnTRW5ITVJ?
A3-KAW MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV71PHdKUUN3ME20O{4yODB5IN88US=> NH3SfXNUSU6JRWK=
CGTH-W-1 NVzOcWQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTR5LkWwOlkh|ryP M2W1THNCVkeHUh?=
DJM-1 NGXHfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof4TWM2OD12Nz61OFE{KM7:TR?= M4D1SnNCVkeHUh?=
A101D NXrwO3hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTR5Lk[zOVch|ryP NEfucnJUSU6JRWK=
BB30-HNC NUG4b4J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M133UGlEPTB;NEiuN|A4OiEQvF2= M{Wx[nNCVkeHUh?=
T98G NV[4Z4tTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT0RY9KSzVyPUS4MlQ3OzNizszN M1\Td3NCVkeHUh?=
NCI-H1573 M1rxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m0XGlEPTB;NEmuOFQ3OiEQvF2= M{K1THNCVkeHUh?=
MEG-01 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDJbpRlUUN3ME20PU44PDFzIN88US=> NXXaUppXW0GQR1XS
WM-115 NUO5fHRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX6dHVpUUN3ME20PU46OjJ{IN88US=> Mnm1V2FPT0WU

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western Blot
DR5/CHOP; 

PubMed: 25531448     


(A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5.

γH2AX/H2AX; 

PubMed: 22933245     


FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX.

pATM; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

53BP1; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

NF-kB; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

pS6/S6; 

PubMed: 24831086     


HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies. 

25531448 22933245 27686740 24831086
Immunofluorescence
DNA damage; 

PubMed: 27686740     


(A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX).

γH2AX; 

PubMed: 28069876     


Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.

27686740 28069876
Growth inhibition assay
Cell viability ; 

PubMed: 25531448     


A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.

25531448
ELISA
IL-8; 

PubMed: 28456021     


ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. 

GLP-1; 

PubMed: 29392078     


Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.

28456021 29392078
In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]
- Collapse

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]
- Collapse
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]
- Collapse
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3
CAS No. 763113-22-0
Storage powder
in solvent
Synonyms Ku-0059436
Smiles C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04515836 Not yet recruiting Drug: Olaparib Mesothelioma|Homologous Recombination Deficiency University of Chicago|AstraZeneca October 15 2020 Phase 2
NCT04024254 Recruiting Drug: Folic Acid Tablet Ovarian Cancer|Breast Cancer|Folic Acid Deficiency Rush University Medical Center July 21 2020 Phase 2|Phase 3
NCT04298021 Recruiting Drug: AZD6738|Drug: Durvalumab|Drug: Olaparib Bile Duct Cancer|Chemotherapy Effect Seoul National University Hospital June 25 2020 Phase 2
NCT04330040 Recruiting Drug: Olaparib Ovarian Cancer|Breast Cancer AstraZeneca May 30 2020 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • Answer:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • Question 2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

selleck catalog

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

  • Selective PARP Inhibitors

    AG-14361 : PARP1-selective, Ki<5 nM.

  • Selective PARP Inhibitors

    UPF 1069 : PARP2-selective, IC50=0.3 μM.

  • Most Potent PARP Inhibitor

    MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.

  • PARP Inhibitor in Clinical Trial

    Iniparib (BSI-201) : Phase III for solid tumors.

  • Newest PARP Inhibitor

    BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

Related PARP Products

  • G007-LK New

    G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.

  • NU1025 New

    NU1025 is a potent PARP inhibitor with IC50 of 400 nM.

  • SCR7 New

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.

  • Veliparib (ABT-888)

    Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

    Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.

  • Rucaparib (AG-014699) phosphate

    Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

    Features:The first PARP inhibitor used in clinical trials combined with temozolomide.

  • Talazoparib (BMN 673)

    Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

    Features:Most potent and selective PARPi reported thus far.

  • Iniparib (BSI-201)

    Iniparib (BSI-201, NSC-746045, IND-71677) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.

  • PJ34 HCl

    PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

    Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).

  • AG-14361

    AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

    Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.

  • A-966492

    A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.

    Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Tags: buy Olaparib (AZD2281) | Olaparib (AZD2281) supplier | purchase Olaparib (AZD2281) | Olaparib (AZD2281) cost | Olaparib (AZD2281) manufacturer | order Olaparib (AZD2281) | Olaparib (AZD2281) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID